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The mangosteen (Garcinia mangostana) is a tropical fruit native to Southeast Asia and has
long been reported to contain multiple health promoting properties.This fruit is an abundant
source of xanthones, a class of polyphenolic compoundswith a distinctive tricyclic aromatic
ring system and is largely responsible for its biological activities including anti-cancer
activity. Herein we describe the anti-cancer activity and mechanisms of mangosteen
polyphenolic xanthones including α-Mangostin against breast cancer and prostate cancer.
So far, extracts and individual xanthones have been found to induce apoptosis and inhibit
proliferation on cancer cells in vitro and in vivo. Based on the reported ﬁndings there is clear
evidence that these polyphenols target multiple signaling pathways involved in cell cycle
modulation and apoptosis. Further work is required to understand its potential for health
promotion and potential drug discovery for prostate and breast cancer chemoprevention.
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THE MANGOSTEEN FRUIT
Themangosteen (Garcinia mangostana) is a tropical fruit native to
SoutheastAsia that has longbeennoted for itsmedicinal andhealth
promoting properties (Obolskiy et al., 2009). Themangosteen tree
is a slow growing plant which ranges from 6 to 25 m in height and
produces ﬂowers that are red and green in color and are roughly 4–
5 cm in size (Obolskiy et al., 2009). The exocarp of the fruit is deep
purple in color with a white pulp and typically contains 6–8 arils
(Chin and Kinghorn, 2008). The fruit has been used for several
hundred years in Southeast Asia for the treatment of wounds,
inﬂammation, and a variety of infections (Chin and Kinghorn,
2008).
DIETARY XANTHONES, A SOURCE OF POLYPHENOLS FROM
THE MANGOSTEEN FRUIT
Recently, themangosteen has been noted to be an abundant source
of a class of polyphenols known as xanthones. The diverse struc-
ture and chemical properties of xanthones have been reported
to have a variety of health promoting properties including anti-
inﬂammatory, anti-oxidant, and anti-cancer activity. The chemical
structure of a xanthone consists of a three ring system which
contains several different functional groups including isoprene,
methoxy, and phenyl groups as well as aromatic protons, phenolic
hydroxyl groups, hydroxyl protons, and dihydrofuran rings (Shan
et al.,2011). Xanthones canbe classiﬁed into several groups includ-
ing simple oxygenated xanthones, prenylated xanthones, xanthone
glycosides, and xanthonolignoids based on these substituents.
To date, more than 60 different xanthones have been iso-
lated from the mangosteen pericarp, bark, and roots including
α-Mangostin, γ-Mangostin, gartanin, 8-deoxygartanin, and 9-
hydroxycalabaxanthone (Obolskiy et al., 2009). A wide variety
of pharmacological activities have been associated with the fruit
and more speciﬁcally the individual xanthones therein have been
shown to target multiple signaling pathways. Among the xan-
thones, α-Mangostin is the most abundant and is also one of the
most studied xanthones due to its potential therapeutic properties.
Due to the increasing incidence of cancer, there has been a
growing interest in themanagement of the disease through dietary
chemoprevention, which is the use of naturally occurring phyto-
chemicals to slow down the process of carcinogenesis. Xanthones,
with their unique physical and chemical properties, are a promis-
ing candidate in the study of dietary chemoprevention due to
their health promoting properties as well as their apparent safety.
It has long been suggested that many xanthones from themangos-
teen fruit, including α-Mangostin, possess anti-cancer properties
including initiation of apoptosis through the regulation of cell
death pathways, the suppression of cancer cell proliferation and
metastasis through inhibition of anti-apoptotic molecules, and
cell cycle arrest (Shan et al., 2011). They have also been observed
to inhibit the initiation, promotion, and progression of carcino-
genesis in several animal models. Xanthones have been shown to
modulate cell signaling pathways that are deregulated in cancer
cells.
In general, xanthone anti-cancer activity has been shown to
decrease with the addition of hydroxyl groups on the 5-carbon
sidechain while the highest anti-cancer activity is seen xan-
thones containing tetraoxygen groupswith two 5-carbon isoprenyl
groups in rings A and B (Obolskiy et al., 2009; Shan et al., 2011).
Of all the xanthones, α-Mangostin has demonstrated the greatest
anti-cancer activity in prostate, breast, lung, and colorectal cancer
(Shan et al., 2011).
In recent years, there has been growing interest in the abil-
ity of natural compounds such as α-Mangostin to serve as
chemopreventive agents in the treatment of prostate and breast
cancer. In most cases the progression of prostate and breast cancer
occurs very slowly, spanning over a period of many years, with very
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distinct stages of initiation, promotion, and progression. Aside
from superﬁcial cancers of the skin, prostate cancer is the sec-
ond leading cause of cancer-related death in the United States
(Arcangeli et al., 2012). Annually, about 660,000 men worldwide
are diagnosed with prostate cancer. The disease typically affects
males over the age of 50 with 80% of cases occurring in men over
the age of 65. In 2010, nearly 1.5 million people were diagnosed
with breast cancer worldwide. In 2011, an estimated 230,480 new
cases of invasive breast cancer will be diagnosed among women in
the United States, as well as an estimated 57,650 additional cases
of in situ breast cancer according to American Cancer Society.
As a result of its long latency, even a small delay in carcinogen-
esis can set back the onset of disease and improve quality of life. It
has been reported that less than 10% of prostate and breast cancer
cases are inherited which suggests that a combination of genetics,
environment, and lifestyle choices may help initiate the develop-
ment of the disease (Carter et al., 1992). Several migratory studies
have demonstrated a link between natural dietary agents and a
lower overall incidence of prostate cancer (Khan and Mukhtar,
2012). Generally, the incidence of prostate cancer is signiﬁcantly
lower in countries where people consume low-fat, plant-based
diets (Arcangeli et al., 2012). This has led investigators to suggest
that the role of the diet is an important factor in contributing to
worldwide cancer incidence.
The lethality of prostate cancer originates from several fac-
tors including high oxidative stress of cancer cells and leading to
the deregulation of multiple cellular signaling pathways including
those responsible for regulating cell proliferation and the initiation
of apoptosis (Johnson et al., 2008). Due to its high incidence, long
latency, and link to diet and lifestyle, chemoprevention through
the use of natural dietary compounds such as α-Mangostin may
be an effective method in the management of breast and prostate
cancer.
ANTI-CANCER ACTIVITY OF MANGOSTEEN EXTRACT
TOWARD BREAST CANCER
In several studies, crude extracts from pericarp of mangosteen
were evaluated for their cytotoxic activity against human breast
adenocarcinoma cell line. In one study (Moongkarndi et al.,
2004a), a crudemethanolic extract (CME) frommangosteen peri-
carp was found to signiﬁcantly inhibit the proliferation of human
breast cancer cell line SKBR3 in a dose-dependent manner with an
ED50 of 9.25± 0.64μg/ml. CMEalso induced apoptosis on SKBR3
cells with the ﬁndings of morphological changes and oligonucle-
osomal DNA fragments. In a second study (Moongkarndi et al.,
2004b), an ethanolic extract from mangosteen pericarp was found
to have anti-proliferative activity on SKBR3 cells with an IC50 of
15.45 ± 0.50 μg/ml. Based on these observations investigators
have begun to evaluate individual xanthones for their anti-cancer
potential in both breast and prostate cancer.
ANTI-CANCER ACTIVITY OF INDIVIDUAL XANTHONES
TOWARD BREAST CANCER
Suksamrarn et al. (2006) evaluated the in vitro cytotoxicity of
19 xanthones from the young fruit (7-week maturity stage) of
mangosteen against different cell lines from human breast cancer
(BC-1) epidermoid carcinoma of the mouth (KB), and small cell
lung cancer (NCI-H187). In BC-1 cells, α-Mangostin was found
to be the most potent with an IC50 value of 0.92 μg/ml (i.e.,
2.24 μM) followed by garcinone E and γ-Mangostin with IC50
values of 1.44 and 1.6 μg/ml, respectively. In total, 13 of 19 xan-
thoneswere observed to decrease cell viability at or below20μg/ml
(Suksamrarn et al., 2006).
Kurose et al. (2012) evaluatedα-Mangostin in the humanbreast
cancer cell line MDA-MB231 observing evidence of apoptosis by
the ﬁndings of signiﬁcantly elevated ssDNA level and caspase 3, 8,
and 9 levels. Signiﬁcant cytochrome c release was also observed
in α-Mangostin-treated cells, suggesting α-Mangostin induced
MDA-MB231 cell apoptosis through the mitochondrial pathway.
α-Mangostin treatment also induced cell cycle arrest through
upregulation of the cyclin-dependent kinase (CDK) inhibitor
p21cip1 and cell cycle checkpoint regulator CHEK2 (Kurose et al.,
2012).
Shibata et al. (2011) evaluated the anti-breast cancer activity
of α-Mangostin on a xenograft metastatic mammary cancer mice
model. In this study, BJMC3879luc2 tumor cells were subcuta-
neously implanted in BALB/c mice. After 3 weeks mini osmotic
pumps were implanted and set to deliver 20 mg/kg/day of α-
Mangostin for a total of 6 weeks. The results indicated that the
α-Mangostin-treated group had a signiﬁcantly higher survival
rate as well as smaller average tumor volume (785 ± 170 and
744 ± 292 mm3 for 10 and 20 mg/kg/day α-Mangostin, respec-
tively vs. 993 ± 612 mm3 for the control). This represents a 21
and 25% smaller tumor in the α-Mangostin treatment groups. In
addition, fewer lymph nodes metastases were observed in treated
mice compared to controls.The authors also observed an increase
of cells in the G1-phase, a decrease of cells in the S-phase and
mitochondria-mediated apoptosis after treating tumor cells with
α-Mangostin in vitro. In addition, they found that α-Mangostin
signiﬁcantly decreased the oncogenic phospho-Akt-threonine 308
expression in both treated breast cancer cells in vitro and breast
cancer tissues in vivo.
Jung et al. (2006) evaluated α-Mangostin and γ-Mangostin for
their anti-cancer activity against preneoplastic lesions induced
by 7,12-dimethylbenz[α]anthracene (DMBA), a powerful organ-
speciﬁc carcinogen, in amousemammary organ culture (MMOC)
system. Brieﬂy, mice were pretreated for 9 days with estradiol and
progesterone, sacriﬁced and mammary glands dissected and sub-
jected to culture for 10 days under appropriate conditions. Glands
were exposed to 2μg/mLDMBA for 24 h then permitted to regress
bywithdrawing all hormones except insulin for 14 additional days.
Xanthones were present in the medium during days 1–10 of cul-
ture; mammary glands were scored for the incidence of lesions.
At a concentration of 10 μg/mL (i.e., 24.36 and 25.23 μM for α-
Mangostin andγ-Mangostin, respectively), the percent inhibitions
of α-Mangostin and γ-Mangostin were 57.1 and 42.9, respec-
tively. α-Mangostin was then further determined to have an IC50
of 1.0 μg/mL (2.44 μM) in a dose–response MMOC assay.
Balunas et al. evaluated the aromatase (estrogen synthase)
inhibitory activity of 12 xanthones from mangosteen pericarp
(Balunas et al., 2008). Garcinone D, garcinone E, α-Mangostin,
and γ-Mangostin were found to have inhibitory activity using a
cell free, enzyme-based microsomal aromatase inhibition assay.
Following the cell-based assay, SKBR3 breast cancer cells which
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are known to express high levels of aromatase were evaluated to
determine if these observations will occur in a cell-based system.
γ-Mangostin was found to be themost potent aromatase inhibitor,
followed by garcinone D, α-Mangostin and garcinone E.
ANTI-CANCER ACTIVITY OF INDIVIDUAL XANTHONES
TOWARD PROSTATE CANCER
Hung et al. (2009) evaluated the anti-metastatic effect of α-
Mangostin in the human prostate carcinoma cell line PC-3,
which originated from bone metastasis. α-Mangostin was found
to inhibit the adhesion, migration, and invasion of PC-3
cells by respective in vitro assays. Further mechanism inves-
tigation found that α-Mangostin signiﬁcantly decreased the
expressions of multiple matrix degrading proteinases, including
matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-
9 (MMP-9), and urokinase-plasminogen activator (u-PA), which
are all required by cancer cell metastasis process. α-Mangostin
also inhibited the phosphorylation of c-Jun N-terminal kinase 1
and 2 (JNK1/2) as well as the activation of nuclear factor kappa
B (NF-κB), oncogene c-Fos and c-Jun, which are all associated
with invasion and metastasis of cancer cells. Similar results were
also foundwhen humanmelanoma cell line SK-MEL-28 and squa-
mous cell carcinoma cell lineA-431were treatedwithα-Mangostin
(Wang et al., 2012).
Han et al. (2009) evaluated the anti-cancer activity of α-
Mangostin on androgen-dependent/androgen responsive human
prostate cancer cell LNCaP in an in vivo hollow ﬁber model. In
brief, LNCaP cells were infused into polyvinylidene ﬂuoride hol-
low ﬁbers. The ﬁbers were then heat sealed at 2 cm intervals and
cut in the middle of seals to generate ﬁbers. Fibers were cultured
overnight, andone set of them is evaluated for viable cell by 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT)
assay. Another set of ﬁbers were intraperitoneally implanted into
NCr nu/nu mice (designated day 0). Mice then received four daily
intraperitoneal injections of α-Mangostin on days 3, 4, 5, and 6.
Onday 7,micewere sacriﬁced andﬁberswere retrieved thenplaced
into 6-well plates, where viable cell mass contained within ﬁbers
were determined with MTT assay. Interestingly, α-Mangostin did
not exhibit cytotoxic activity against LNCaP cells in the hollow
ﬁber model at a range of doses from 2.5 mg/kg up to 20 mg/kg.
Possible explanation is that the 7-day study is too short for α-
Mangostin to show efﬁcacy or 20 mg/kg of α-Mangostin is not
enough to achieve an observable cytotoxicity on LNCaP cells in
the speciﬁc model.
Recently, we evaluated the anti-cancer activity of α-Mangostin
on several human prostate cancer cell lines as well as a xenograft
mouse model (Johnson et al., 2012). α-Mangostin was found to
have signiﬁcantly lower IC50 values on all four prostate cancer cell
lines (LNCaP, 22Rv1, DU145, and PC-3) compared to epigallo-
catechin 3-gallate (EGCG), genistein, and 3,3′-diindolylmethane
(DIM). The IC50 of α-Mangostin was 5.9, 6.9, 22.5, and 12.7 μM
for LNCaP, 22Rv1, DU145, and PC3, respectively. Interestingly,
when human normal prostate epithelial cells (PrECs) were treated
with 15 μM of α-Mangostin there was no observable inhibi-
tion on cell growth compared to control cells.In prostate cancer
cells α-Mangostin was also found to inhibit colony formation
and induce G1 cell cycle arrest. Further mechanism investiga-
tion found that 10 μM α-Mangostin signiﬁcantly inhibited the
kinase activity of cyclinA1/CDK2 (34.2% ± 0.1), cyclinA2/CDK2
(13.2% ± 0.4), cyclinD1/CDK4 (59.2 ± 1.4), and cyclinD3/CDK6
(5.5% ± 0.3). No direct inhibition of kinase activity was observed
on JNK1 or JNK2 at 1 or 10 μM α-Mangostin which is incon-
sistent with the above-mentioned study for unknown reason.
When we detected the possible expression changes of proteins
upstream of CDK4 that included the INK proteins, p27 Kip1
and CDK4 in 22Rv1 cells, we found an increase in p27 Kip1.
This was in agreement with a previous study of α-Mangostin
on human colon cancer DLD-1 cells (Matsumoto et al., 2005)
and p27 overexpression has been reported to induce apoptosis
in several different cancer cell lines (Katayose et al., 1997; Wang
et al., 1997). Further, the previous study found that α-Mangostin
downregulated the expression of cyclinA and cyclinD1, which
is also in concert with our kinase inhibition results. In addi-
tion, a dose-dependent decrease in the downstream targets of
CDK4, speciﬁcally the phosphorylation sites of retinoblastoma
protein at residues Ser780, Ser795, and Ser807/811, was observed.
Based on these results and molecular modeling, we generated
an α-Mangostin/CDK4 binding hypothesis. Our data provided
a more thorough molecular understanding to previous reports of
α-Mangostin decreasing cell viability and promoting G1 cell cycle
arrest (Matsumoto et al., 2003, 2004, 2005). Next, mice were sub-
cutaneously implanted with 22Rv1 cells followed and treated with
α-Mangostin (100 mg/kg orally) resulting in a 65% smaller tumor
in the treatment group.
CONCLUSION
In recent years, the mangosteen has become a popular dietary
supplement for its potential health promoting properties. The
mangosteen fruit is unique in that it is the most abundant source
of a diverse “natural” chemical library of xanthones and is largely
responsible for their health promoting properties. In light of the
interesting observations of these xanthones to modulate multi-
ple signaling pathways it is clear that further work is required
to understand its potential for health promotion and potential
drug discovery. This is especially true in that the mangosteen
fruit is becoming a popular dietary supplement and juice in recent
years.
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